Apollo Health Ventures

Apollo Health Ventures is a transatlantic early-stage venture capital firm focused on co-founding and investing in transformative healthcare companies. The firm targets age-related diseases and the biology of aging, aiming to enhance healthy lifespan and reduce healthcare spending. By leveraging biotechnology and scientific breakthroughs, Apollo Health Ventures seeks to impact human health significantly within the next decade.

The firm's investment strategy combines traditional funding with active venture building, accomplishing a bigger and more diverse value creation in Europe and the US. In their Venture Lab, they partner with scientific experts to turn untapped technologies into transformational companies, acquiring founder shares at nominal value and offering unique upsides to investors. They also identify and invest in best-in-class companies at an early stage, helping them accelerate based on breakthrough science and leadership.

Apollo Health Ventures supports its portfolio companies with scientific and operational expertise, building top teams, providing access to capital and strong syndicates, and minimizing risks by conducting 'killer experiments'. They also assist with talent and leadership recruitment, guidance on R&D, and clinical trial and indication selection strategies.

The firm has a successful track record since 2017, with a portfolio that includes companies like Aeovian Pharmaceuticals, Auron Therapeutics, Bloom Science, Booster Therapeutics, Cleara Biotech, and Focal Biosciences. Their offices are located in Berlin, Hamburg, and Boston, enabling them to effectively manage their transatlantic activities.